Fig. 1From: Similar immunogenicity profiles between the proposed biosimilar MYL-1501D and reference insulin glargine in patients with diabetes mellitus: the phase 3 INSTRIDE 1 and INSTRIDE 2 studiesStudy design of (a) INSTRIDE 1 and (b) INSTRIDE 2. T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitusBack to article page